Impact of body mass index on overall survival in patients with metastatic breast cancer

被引：22

作者：

Saleh, Khalil ^{[1
]}

Carton, Matthieu ^{[2
,3
]}

Dieras, Veronique ^{[4
]}

Heudel, Pierre-Etienne ^{[5
]}

Brain, Etienne ^{[6
]}

D'Hondt, Veronique ^{[7
]}

Mailliez, Audrey ^{[8
]}

Patsouris, Anne ^{[9
]}

Mouret-Reynier, Marie-Ange ^{[10
]}

Goncalves, Anthony ^{[11
]}

Ferrero, Jean Marc ^{[12
]}

Petit, Thierry ^{[13
]}

Emile, George ^{[14
]}

Uwer, Lionel ^{[15
]}

Debled, Marc ^{[16
]}

Dalenc, Florence ^{[17
]}

Jouannaud, Christelle ^{[18
]}

Ladoire, Sylvain ^{[19
]}

Leheurteur, Marianne ^{[20
]}

Cottu, Paul ^{[6
,21
]}

Veron, Lucie ^{[1
]}

Savignoni, Alexia ^{[2
,3
]}

Courtinard, Coralie ^{[22
]}

Robain, Mathieu ^{[22
]}

Delaloge, Suzette ^{[1
]}

Deluche, Elise ^{[1
,23
]}

机构：

[1] Gustave Roussy, Dept Canc Med, 114 Rue Edouard Vaillant, F-94800 Villejuif, France

[2] Inst Curie, Dept Biostat, 26 Rue DUlm, F-75005 Paris, France

[3] Inst Curie, Dept Biostat, 26 Rue DUlm, F-75005 St Cloud, France

[4] Ctr Eugene Marquis, Med Oncol Dept, Ave La Bataille Flandres Dunkerque, F-35000 Rennes, France

[5] Ctr Leon Berard, Dept Med Oncol, 28 Prom Lea & Napoleon Bullukian, F-69008 Lyon, France

[6] Inst Curie, Dept Med Oncol, 26 Rue DUlm, St Cloud, France

[7] Univ Montpellier, Inst Canc Montpellier, Dept Med Oncol, INSERM U1194, 208 Rue Apothicaires, F-34298 Montpellier, France

[8] Ctr Oscar Lambret, Med Oncol Dept, 3 Rue Freder Combemale, F-59000 Lille, France

[9] Inst Cancerol LOuest Nantes & Angers, Dept Med Oncol, 15 Rue Andre Boquel, F-49055 Angers, France

[10] Ctr Jean Perrin, Dept Med Oncol, 58 Rue Montalembert, F-63011 Clermont Ferrand, France

[11] Inst Paoli Calmettes, Dept Med Oncol, 232 Blvd St Marguerite, F-13009 Marseille, France

[12] Ctr Antoine Lacassagne, Dept Med Oncol, 33 Ave Valambrose, F-06189 Nice, France

[13] Ctr Paul Strauss, Dept Med Oncol, 3 Rue La Porte Hop, F-67000 Strasbourg, France

[14] Ctr Francois Baclesse, Dept Med Oncol, 3 Ave Gen Harris, F-14000 Caen, France

[15] Inst Cancerol Lorraine, Dept Med Oncol, 6 Ave Bourgogne, F-54519 Vandoeuvre Les Nancy, France

[16] Inst Bergonie, Dept Med Oncol, 229 Cours Argonne, F-33000 Bordeaux, France

[17] Inst Claudius Regaud IUCT Oncopole, Dept Med Oncol, 1 Ave Irene Joliot Curie, F-31059 Toulouse, France

[18] Inst Cancerol Jean Godinot, Dept Med Oncol, 1 Rue Gen Koenig, F-51100 Reims, France

[19] Ctr Georges Francois Leclerc, Dept Med Oncol, 1 Rue Prof Mar, F-21079 Dijon, France

[20] Ctr Henri Becquerel, Dept Med Oncol, Rue DAmiens, F-76000 Rouen, France

[21] Inst Curie, Dept Med Oncol, 26 Rue DUlm, F-75005 Paris, France

[22] R&D Unicanc, Dept Res & Dev, 101 Rue Tolbiac, F-75654 Paris, France

[23] CHU Limoges, Dept Med Oncol, 2 Ave Martin Luther King, Limoges, France

来源：

BREAST | 2021年 / 55卷

关键词：

Metastatic breast cancer; Overall survival; BMI; Underweight; Obesity; PROGNOSIS; OBESITY; CHEMOTHERAPY; OUTCOMES; RISK; METAANALYSIS; PREDICTORS; OVERWEIGHT; SARCOPENIA; TOXICITY;

D O I：

10.1016/j.breast.2020.11.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: High Body mass index (BMI) is a risk factor for breast cancer among postmenopausal women and an adverse prognostic factor in early-stage. Little is known about its impact on clinical outcomes in patients with metastatic breast cancer (MBC). Methods: The National ESME-MBC observational cohort includes all consecutive patients newly diagnosed with MBC between Jan 2008 and Dec 2016 in the 18 French comprehensive cancer centers. Results: Of 22 463 patients in ESME-MBC, 12 999 women had BMI data available at MBC diagnosis. Median BMI was 24.9 kg/m(2) (range 12.1-66.5); 20% of women were obese and 5% underweight. Obesity was associated with more de novo MBC, while underweight patients had more aggressive cancer features. Median overall survival (OS) of the BMI cohort was 47.4 months (95% CI [46.2-48.5]) (median follow-up: 48.6 months). Underweight was independently associated with a worse OS (median OS 33 months; HR 1.14, 95%CI, 1.02-1.27) and first line progression-free survival (HR, 1.11; 95%CI, 1.01; 1.22), while overweight or obesity had no effect. Conclusion: Overweight and obesity are not associated with poorer outcomes in women with metastatic disease, while underweight appears as an independent adverse prognostic factor. (C) 2020 The Author(s). Published by Elsevier Ltd.

引用

页码：16 / 24

页数：9